Evidence map›Paper›PMID 39412702›Full record

ArticleEJNMMI radiopharmacy and chemistry2024

First-in-human study of D6-[

Ruiyue Zhao, Jinhua Chen, Ting Ye, Jianmin Chu, Jingwen Li, Yan Zhang, Siran Xu, Shaoyu Liu, Ling Chen, Karl Ploessl and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Comparison betweenQuantitative imaging in medicine and surgery · 2026
    Article
  2. Multitype hand writing as a digital marker for Parkinson's disease.Clinical parkinsonism & related disorders · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruiyue ZhaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Jinhua ChenDepartment of Neurology, Department and Key Discipline of Neurology, National Key Clinical, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Ting YeDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Jianmin ChuDepartment of Neurology, Department and Key Discipline of Neurology, National Key Clinical, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Jingwen LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Yan ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Siran XuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Shaoyu LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Ling ChenDepartment of Neurology, Department and Key Discipline of Neurology, National Key Clinical, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Karl PloesslFive Eleven Pharma Inc.,, Philadelphia, PA, 19104, USA.
David AlexoffFive Eleven Pharma Inc.,, Philadelphia, PA, 19104, USA.
Hank F KungFive Eleven Pharma Inc.,, Philadelphia, PA, 19104, USA. kunghf@gmail.com.
Lin ZhuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China. zhulin111@gmail.com.
Xinlu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China. 71lu@163.com.ORCID http://orcid.org/0000-0003-1997-5687

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2023A04J1196Guangdong Regional Joint Fund 2022A1515110941Guangzhou Basic and Applied Basic Research 2024A03J1228Key Realm R&D Program of Guangdong Province 2018B030337001National Natural Science Foundation of China 82271267
6 · The paper itself

Abstract

backgroundIn the central nervous system, type 2 vesicular monoamine transporters (VMAT2) are responsible for the reuptake of monoamines from synaptic junction back to pre-synaptic terminal vesicles. These transporters are functionally crucial as they reflect the integrity of monoamine neurons. D6-[

resultsThe automated synthesis of D6-[

conclusionsD6-[

Indexed as

AV-133Deuterium substitutionDosimetryParkinson’s diseaseVesicular monoamine transporter 2

Identifiers

PMID39412702
PMCPMC11484983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.